51results about How to "Inducing effect" patented technology

Cosmetic method and apparatus are provided that can provide cooling and / or freezing of skin tissue proximal to the skin surface to generate an appearance of lightening or reduced pigmentation in the skin. The skin can be cooled to a temperature of less than about −5 degrees Celsius for a duration of about one minute or less, using a cooled surface that is at least 3 cm in width. A cooling arrangement can be provided to provide controlled heat removal from the skin tissue being treated. A sensor can optionally be provided to detect freezing of tissue proximal to the cooled surface.

Cosmetic method and apparatus are provided that can provide cooling and / or freezing of skin tissue proximal to the skin surface to generate an appearance of lightening or reduced pigmentation in the skin. The skin can be cooled to a temperature of less than about −5 degrees Celsius for a duration of about one minute or less, using a cooled surface that is at least 3 cm in width. A cooling arrangement can be provided to provide controlled heat removal from the skin tissue being treated. A sensor can optionally be provided to detect freezing of tissue proximal to the cooled surface.

Modified n atriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved half-life in circulation as compared to unmodified counterpart natriuretic compounds. Oral, parenteral, subcutaneous, and intravenous forms of the compounds and conjugates may be prepared as treatments and / or therapies for heart conditions particularly congestive heart failure. Modifying moieties comprising oligomeric structures having a variety of lengths and configurations are also disclosed. Analogs of the n atriuretic compound are also disclosed, having an amino acid sequence that is other than the native sequence.

The invention provides for compositions and methods of reducing pain in a subject by administering a combination of mu-opioid receptor agonist, kappa1-opioid receptor agonist and a nonselective opioid receptor antagonist in amounts effective to reduce pain and ameliorate an adverse side effect of treatment combining opioid-receptor agonists. The invention also provides for methods of enhancing an analgesic effect of treatment with an opioid-receptor agonist in a subject suffering from pain while reducing an adverse side effect of the treatment. The invention also provides for methods of reducing the hyperalgesic effect of treatment with an opioid-receptor agonist in a subject suffering from pain while reducing an adverse side effect of the treatment. The invention further provides for methods of promoting the additive analgesia of pain treatment with an opioid-receptor agonist in a subject in need while reducing an adverse side effect of the treatment.

A method of fabricating transistors includes: providing a substrate including an N-type well and P-type well; forming a first gate on the N-type well and a second gate on the P-type well, respectively; forming a third spacer on the first gate; forming an epitaxial layer in the substrate at two sides of the first gate; forming a fourth spacer on the second gate; forming a silicon cap layer covering the surface of the epitaxial layer and the surface of the substrate at two sides of the fourth spacer; and forming a first source / drain doping region and a second source / drain doping region at two sides of the first gate and the second gate respectively.

The present invention provides a cancer vaccine composition for transdermal administration for cellular immunity induction, comprising (i) a WT1 peptide and / or a modified WT1 peptide; and (ii) a pharmacologically acceptable acid as a first cellular immunity induction promoter, or a pharmacologically acceptable salt thereof.

Self-propagating, fusogenic blebs are produced from cells infected with a population of Venezuelan Equine Encephalitis virus replicon particles (VRP). The self-propagating, fusogenic nature of the blebs is derived from expression of heterologous genes encoding viral fusion proteins that are incorporated into the replication defective replicon particles. The resulting blebs can be harvested from supernatants of cells displaying severe cytopathic effects. The blebs are used to make immunogenic compositions and devise methods of immunizing mammals against paramyxoviruses such as parainfluenza virus type 3.

A moving image converting apparatus includes: a block dividing unit executing block division processing for each of frames that form the moving image data; a motion amount detecting unit detecting a block motion amount corresponding to a motion amount of an object contained in each of blocks obtained; a line-of-sight motion amount detecting unit calculating a line-of-sight motion amount of a viewer who views the moving image data; a sampling point phase change amount determining unit receiving the block motion amount and the line-of-sight motion amount as input, and determining a block-corresponding sampling point phase change amount to be applied to spatial decimation processing on each of the blocks; and a decimation executing unit receiving the blocks obtained as input, executing the spatial decimation processing on the inputted blocks, the spatial decimation processing being executed by applying the block-corresponding sampling point phase change amount determined.

The present invention relates to compositions and methods for preventing the development of epithelial ovarian cancer by administering compounds in an amount capable of regulating TGF-β expression in the ovarian epithelium and / or capable of optimally altering expression of other surrogate biomarkers identified by microarray technology. HRT and OCP regimens comprising such compositions and methods are disclosed.

According to an embodiment of the invention, a radiation detector device (10) for detecting a primary radiation (6) comprises a scintillator (12) which generates a converted primary radiation in response to incoming primary radiation (6) and a photo detector (14) for detecting the converted primary radiation. The radiation detector device (10) further comprises a secondary radiation source (20) for irradiating the scintillator (12) with a secondary radiation (22) which has a wavelength different from a wavelength of the first radiation (6) and which is capable of producing a spatially more uniform response of the scintillator (12) to primary radiation. In an embodiment of the invention, the radiation detector device (10) is an X-ray detector of an X-ray imaging apparatus where the primary radiation is X-ray radiation and the secondary radiation has a wavelength between 350 nm and 450 nm. According to an embodiment, the irradiation with the secondary radiation, e.g. UV radiation, produces a uniform gain distribution of the X-ray detector (10).

The invention provides a vaccine composition for transdermal or transmucosal administration for inducing cellular immunity, comprising (i) an antigen; and (ii) a pharmacologically acceptable acid or a pharmacologically acceptable salt thereof as a first cellular immunity induction promoter.

Disclosed is an optical composite for use in a backlight unit of a liquid crystal display or an illumination apparatus, which is able to sufficiently increase luminance and in which adhesion portions are regularly arranged to thus induce an optical illusion effect so that scratches or stains cannot be seen clearly. A method of manufacturing such an optical composite is also provided. There is no need to additionally use optical films or prism sheets, thus making it possible to inexpensively manufacture optical devices, such as backlight units.

The present invention provides a vaccine composition which comprises a cellular immunity induction promoter universally usable against various antigens in cellular immunity induction by mucosal administration of the antigen and exerts a high cellular immunity inducing effect by mucosal administration. The present invention provides a vaccine composition for mucosal administration to induce cellular immunity, comprising: (i) an antigen; and (ii) one or more cellular immunity induction promoters selected from the group consisting of a TLR ligand, a cyclic dinucleotide, a helper peptide and an immunomodulatory small molecule drug.

Anti-tumor conjugates, which consists of foliate or analogues thereof, linkers, an antibodies such as immunoglobulin G. The linker comprises glutathione, cysteamine or cysteine residue, and further comprises N-hydroxysuccinimide. The Conjugates target folate-receptor-positive tumor cells. Also provided are preparation methods and anti-tumor and anti-autoimmune disease uses of the conjugates.

High sensitivity in a CPP spin valve has been achieved by providing an extended free layer while maintaining good bias point control and edge domain control through use of exchange coupling with the whole free layer. In a second embodiment of the invention, a second spin valve is added so that the free layer receives filtered electrons from two directions. Processes to manufacture both embodiments are also described.

The chemically peeling agent contains a component (A) having the following general formula:(wherein B is an alcohol residue;AO is an alkylene-oxy group having 3 to 18 carbon atoms;a is an integer of 1 or more;m is an integer of 4 or more; andn is 0 or an integer of 1 or more;provided that a molar amount m of the oxidized ethylene to be added is a value that amounts to 40% or more of the entire molecular weight of an ethylene oxide chain moiety)and a phenol compound (B) formulated in an amount ranging from 10% to 30% by weight.

A slow Magic-Angle Spinning NMR device and method are detailed that provide high resolution and high sensitivity metabolic profiling of biological samples. A new 1H-PASS sequence suppresses line broadening in the various biological samples. The device and method allow metabolic changes in small animals to be tracked through continuous investigations of minimally-invasive blood and tissue biopsy samples over a sustained period and allow intact biological objects with sizes up to a few centimeters to be studied.

A method of fabricating transistors includes: providing a substrate including an N-type well and P-type well; forming a first gate on the N-type well and a second gate on the P-type well, respectively; forming a third spacer on the first gate; forming an epitaxial layer in the substrate at two sides of the first gate; forming a fourth spacer on the second gate; forming a silicon cap layer covering the surface of the epitaxial layer and the surface of the substrate at two sides of the fourth spacer; and forming a first source / drain doping region and a second source / drain doping region at two sides of the first gate and the second gate respectively.

Provided herein is a method for treating a pulmonary disease using mesenchymal stem cell-derived artificial nanosomes exhibiting a significantly excellent capability to regenerate alveoli compared to mesenchymal stem cells themselves and natural exosomes derived from human adipose-derived mesenchymal stem cells, wherein the mesenchymal stem cell-derived artificial nanosomes of the present disclosure may be collected through a simple production method using an extruder and an ultracentrifuge, instead of treating mesenchymal stem cells with a separate chemical substance and the potential side effects caused by stem cell therapeutic agents is low.

A radiation detector device for detecting a primary radiation includes a scintillator which generates a converted primary radiation in response to incoming primary radiation and a photo detector for detecting the converted primary radiation. The radiation detector device further includes a secondary radiation source for irradiating the scintillator with a secondary radiation which has a wavelength different from a wavelength of the first radiation and which is capable of producing a spatially more uniform response of the scintillator to primary radiation.

A basketball goal provides a support that has upper and lower end portions. A backboard is affixed to the upper end portion of the support. A hoop or rim is affixed to the backboard. A jacking mechanism elevates the hoop when the hoop pivots downwardly when a player dunks a basketball through the hoop or rim. In such a case, the player typically contacts the rim or hoop with his or her hands or hand forcing it downwardly. With each such dunk shot, the rim or hoop is deflected downwardly and the jacking mechanism elevates the hoop about half an inch. A control positioned on the support enables the hoop to be selectively used in the jacking mode or in a fixed mode wherein the hoop or rim is affixed to a selected position in a selected elevation thus overriding the jacking mechanism. The control has multiple selectable positions including a position that engages the jacking mechanism and a fixed position that overrides the jacking mechanism. A third mode can be optionally provided that lowers the hoop or rim when the control is placed in the third, lowering position.

A tunable optical filter comprising an index grating produced in a waveguide defining a longitudinal direction of propagation of an incident optical signal, said grating being defined by a plurality of optical parameters, is characterized in that the optical guide contains semiconductor nanoparticles and in that the index grating is made up of a refractive index variation in the guide that is at least partly induced by a Kerr effect linked to the 3rd order dielectric susceptibility (χ3) of said nanoparticles, at least one of said parameters of said index grating being modified by application of an optical control signal coupled into the guide and propagating longitudinally in said guide.

Provided are compositions comprising an active ingredient having antispasmodic and / or prokinetic activity, preferably vicenin 2 or biologically active analogues thereof.

The present invention provides a cancer vaccine composition for transdermal administration for cellular immunity induction, comprising (i) a WT1 peptide and / or a modified WT1 peptide; and (ii) a pharmacologically acceptable acid as a first cellular immunity induction promoter, or a pharmacologically acceptable salt thereof.

There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

The invention discloses an animal continuous inhalation anesthesia instrument with an induction function, and belongs to the technical field of medical instruments. The animal continuous inhalation anesthesia instrument comprises a mask; a projection curtain is arranged in the mask; a hard pad is fixedly connected to the end surface of the mask; and a clamping groove is formed in the surface, close to the projection curtain, of the hard pad. According to the instrument, through the mutual cooperation of the designed structures such as the projection curtain, a micro projector, an anesthetic volatilization enhancer, a high-pressure oxygen bottle, a first one-way valve pipe, a second one-way valve pipe, a gas separation membrane, a filter chamber and a one-way waste gas recovery tank and thelike, the smell of food is guided into the mask and is matched with a food picture, so that the induction effect can be further improved, anesthetic can be synchronously input into the respiratory tract of a pet in the food smell smelling process of the pet, subsequent treatment can be conducted by wearing the mask on the face of the pet, exhaled waste gas can be separated, purified and recycled,and the utilization rate of oxygen and the anesthetic is increased.

A memory structure includes: a substrate; a control gate positioned on the substrate; floating gates positioned at two sides of the control gate, wherein the floating gates have a U-shaped bottom embedded in the substrate; a first dielectric layer positioned between the control gate and the substrate; a second dielectric layer positioned between the U-shaped bottom of the floating gates and the substrate; a third dielectric layer positioned between the control gate and the floating gates; a local doping region positioned around the floating gates channel; and a source / drain doping region positioned in the substrate at a side of the floating gates.